These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33850579)

  • 21. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.
    Patti G; Pecen L; Casalnuovo G; Manu MC; Kirchhof P; De Caterina R
    Clin Res Cardiol; 2023 Nov; 112(11):1517-1528. PubMed ID: 35976428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study.
    Inoue H; Umeyama M; Yamada T; Hashimoto H; Komoto A; Yasaka M
    J Arrhythm; 2019 Jun; 35(3):506-514. PubMed ID: 31293700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
    Choi EK; Lin WS; Hwang GS; Kirchhof P; De Caterina R; Chen C; Unverdorben M; Wang CC; Kim YH
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program.
    Yasaka M; Uchiyama S; Atarashi H; Okumura K; Koretsune Y; Yamashita T; Taniguchi A; Fukaya T; Inoue H;
    J Stroke Cerebrovasc Dis; 2020 May; 29(5):104717. PubMed ID: 32113736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation　- SAMURAI-NVAF Study.
    Yoshimura S; Koga M; Sato S; Todo K; Yamagami H; Kumamoto M; Itabashi R; Terasaki T; Kimura K; Yagita Y; Shiokawa Y; Kamiyama K; Okuda S; Okada Y; Takizawa S; Hasegawa Y; Kameda T; Shibuya S; Nagakane Y; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Fujita K; Kamimura T; Ando D; Ide T; Yoshimoto T; Shiozawa M; Matsubara S; Yamaguchi Y; Kinoshita N; Matsuki T; Takasugi J; Tokunaga K; Higashida K; Homma K; Kario K; Arihiro S; Toyoda K;
    Circ J; 2018 Jun; 82(7):1935-1942. PubMed ID: 29863095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry.
    Guo X; Du J; Yang Y; Wu M; Ou W; Han X; Wang Z; Jin J; Zhang P; Zhang Z; Chen G; Long M; Yin G; Liu T; Wang X; Li D; Chen M; Dong Y; Lai C; Zhang X; Yi Y; Xiang J; Chen C; Unverdorben M; Ma C;
    Sci Rep; 2024 Feb; 14(1):2778. PubMed ID: 38307927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
    de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
    Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
    J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
    Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ogawa S; Minematsu K; Ikeda T; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Ohashi Y; Takeichi M; Okayama Y; Yamanaka S; Inuyama L
    J Arrhythm; 2018 Apr; 34(2):167-175. PubMed ID: 29657592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
    Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
    N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
    De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry.
    Okumura K; Yamashita T; Akao M; Atarashi H; Ikeda T; Koretsune Y; Shimizu W; Suzuki S; Tsutsui H; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Morishima Y; Takita A; Inoue H
    JACC Asia; 2022 Nov; 2(6):720-733. PubMed ID: 36444326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients　- A Subanalysis of the ENVISAGE-TAVI AF Trial.
    Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
    Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of edoxaban
    Alsultan MM; Alahmari AK; Mahmoud MA; Almalki ZS; Alzlaiq W; Alqarni F; Alsultan F; Ahmed NJ; Alenazi AO; Scharf L; Guo JJ
    Front Pharmacol; 2023; 14():1276491. PubMed ID: 38035002
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry.
    Yoshimoto T; Toyoda K; Ihara M; Inoue H; Yamashita T; Suzuki S; Akao M; Atarashi H; Ikeda T; Okumura K; Koretsune Y; Shimizu W; Tsutsui H; Hirayama A; Yasaka M; Maruyama H; Teramukai S; Kimura T; Morishima Y; Takita A; Yamaguchi T
    Stroke; 2022 Aug; 53(8):2549-2558. PubMed ID: 35440169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.